Literature DB >> 3568278

High dose etoposide does not cause peripheral neuropathy.

T J Littlewood, D P Bentley, I N McQueen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3568278     DOI： 10.1007/bf00254577

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  5 in total

1.  A clinical trial of the oral form of 4'-demethyl-epipodophyllotoxin-beta-D ethylidene glucoside (NSC 141540) VP 16-213.

Authors:  G Falkson; J J van Dyk; E B van Eden; A M van der Merwe; J A van den Bergh; H C Falkson
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

Review 2.  Review of etoposide.

Authors:  N C Phillips; R D Lauper
Journal:  Clin Pharm       Date:  1983 Mar-Apr

3.  Etoposide--chemistry, preclinical and clinical pharmacology.

Authors:  W Achterrath; N Niederle; R Raettig; P Hilgard
Journal:  Cancer Treat Rev       Date:  1982-06       Impact factor: 12.111

4.  Possible enhancement of vincristine neuropathy by VP-16.

Authors:  M Thant; R J Hawley; M T Smith; M H Cohen; J D Minna; P A Bunn; D C Ihde; W West; M J Matthews
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

5.  Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213.

Authors:  D V Jackson; H B Wells; D R White; H B Muss; F Richards; M R Cooper; J J Stuart; E K Pope; C L Spurr
Journal:  Am J Clin Oncol       Date:  1983-06       Impact factor: 2.339
  5 in total
  1 in total

Review 1.  Etoposide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in combination chemotherapy of cancer.

Authors:  J M Henwood; R N Brogden
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.